Press Releases

Considering the emerging need for medicines for the paediatric segment in the country and taking its acquisition drive forward, JB Pharma has announced its 3rd acquisition of 4 brands in the calendar year in the paediatric segment – “Z&D”, “Pedicloryl”, “Pecef” and “Ezinapi” from Dr Reddy’s Laboratories. All four brands – “Z&D”, “Pedicloryl”, “Pecef” and “Ezinapi&rdquo

MultiOmic Health, an artificial intelligence (AI)-enabled drug discovery company, and Mesh Bio, a digital health startup transforming chronic disease management through predictive analytics, today announce their partnership to conduct an observational clinical study on patients with chronic metabolic disease and increased risk of complications such as chronic kidney disease. The partnership will provide access to data from patient populations in Asia that have historically been underrepresent

Akebia Therapeutics®, Inc.  a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it has executed an agreement to terminate the U.S. and ex-U.S. vadadustat Collaboration and License Agreements with Otsuka Pharmaceutical Co., Ltd. (Otsuka). As part of the termination, Otsuka has agreed to pay Akebia a settlement fee of $55 million. As a result of the termination of the agreements, Akebia is regaining the r

TetraScience, the R&D Data Cloud company, announced today that Chemaxon, a leading web-based cheminformatics and bioinformatics software provider, has joined the Tetra Partner Network to help customers dramatically increase their capacity to find and synthesize chemical compounds with overall improved property profiles. "Chemaxon is an industry leader with flexible solutions that support computational chemistry," said Simon Meffan-Main, Ph.D., Vice President, Tetra Par

Ascentage Pharma , a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that its novel inhibitor of the embryonic ectoderm development (EED) protein, APG-5918, has been cleared by the US Food and Drug Administration (FDA) to enter a first-in-human (FIH) study that will assess the safety, pharmacokinetics, and preliminary efficacy of APG-5918 in patients with solid tumors or hematologic malign

Domain Therapeutics, a biopharmaceutical company focusing on the research and development of innovative drugs targeting G Protein-Coupled Receptors (GPCRs) in immuno-oncology (IO), today announced that it obtained a single digit multimillion milestone payment from Merck as part of the €240m ($261m) milestone payments and undisclosed royalties collaboration and license partnership signed in 2017. M1069 is an orally available small molecule antagonist of adenosine receptors disco

NewAmsterdam Pharma , a clinical-stage company focused on the research and development of transformative oral therapies for major metabolic diseases, and the Menarini Group (Menarini), an Italy-based, privately held, international pharmaceutical company, today announced an exclusive license agreement for the commercialization of obicetrapib, if approved, in Europe, either as a monotherapy or as part of a fixed dose combination with ezetimibe, for cardiovascular diseases. Obicetrapib is NewAms

Advicenne (Euronext Growth Paris ALDVI - FR0013296746) (Paris:ALDVI), a specialty pharmaceutical company dedicated to developing and commercializing innovative treatments for those suffering from rare renal diseases, is pleased to announce that it has signed an exclusive distribution agreement with Taïba Healthcare (“Taïba”), a leading pharmaceutical company based in Sultanate of Oman, for the commercialization of Sibnayal® in selected Middle-East countries (Kingdom

Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) indications, today announces the US Food and Drug Administration (FDA) has authorized an Investigational New Drug (IND) application to initiate the Orpheus Phase 2b study of Noema’s PDE10A inhibitor gemlapodect (NOE-105) in Childhood Onset Fluency Disorder (COFD, also known as stuttering). The Orpheus Phase 2b study is a multi-center, 11-week prospective, placebo-controlled study

Ixaka Ltd, an integrated cell and gene therapy company, and Minaris Regenerative Medicine GmbH (“Minaris”), a leading contract development and manufacturing service provider for the cell and gene therapy industry, today announced that they have signed an agreement to enable technology transfer as well as clinical and commercial manufacture of REX-001, Ixaka’s lead autologous multi-cell therapy (MCT) being developed for the treatment of chronic limb-threatening ischemia (CLTI